Cannabicyclol (CBL)

Cannabicyclol (CBL) is a non-psychoactive minor phytocannabinoid of Cannabis sativa, classified within the CBL-type structural family and characterized by a molecular formula of C21H30O2 (molecular weight 314.46 g/mol) and a unique tricyclic ring system consisting of fused four-, five-, and six-membered rings bearing four contiguous stereocenters. The compound is not produced by a dedicated enzymatic pathway in the plant but arises indirectly as a photochemical degradation product of cannabichromene (CBC) through a [2+2] intramolecular cycloaddition of the chromene double bond system under ultraviolet irradiation or prolonged light exposure. First identified by Korte and Sieper in 1964 (initially designated "THC III"), structurally revised by Mechoulam and Gaoni in 1967 and Claussen and colleagues in 1968, and confirmed by X-ray crystallography (Whiting et al., 1970), cannabicyclol remained one of the least pharmacologically characterized phytocannabinoids for over five decades.

The pharmacological profile of CBL was transformed by the Haghdoost et al. (2025) report in the Journal of Natural Products, which demonstrated that CBL is a potent positive allosteric modulator (PAM) of the serotonin 5-HT1A receptor. In radioligand binding assays, CBL displaced [3H]-8-OH-DPAT at the 5-HT1A receptor (75 percent inhibition at 10 micromolar) while exhibiting negligible affinity for CB1 and weak affinity for CB2 cannabinoid receptors. Functionally, CBL acted as a weak direct agonist (approximately 15 percent maximal efficacy at 12 micromolar) but as an exceptionally potent positive allosteric modulator of serotonin-induced beta-arrestin recruitment, with an EC50 of 5 nanomolar at 40 nanomolar serotonin concentration. At 4 micromolar, CBL increased serotonin-induced beta-arrestin recruitment from 20 percent to 80 percent of maximal receptor activation. This PAM activity at 5-HT1A has not been reported for other naturally occurring phytocannabinoids, including delta-9-tetrahydrocannabinol, cannabidiol, cannabichromene, or cannabinol, positioning CBL as a structurally and mechanistically distinct member of the cannabinoid family.

Preclinical pharmacology for CBL beyond the 5-HT1A characterization remains limited. Early reports from the cannabinoid survey literature attributed weak anti-inflammatory activity (inhibition of prostaglandin synthesis) and modest antimicrobial effects to CBL, though at potencies below those of cannabidiol and cannabichromene. No in vivo pharmacology, pharmacokinetic, or clinical data have been published for CBL as of the date of this monograph. The compound is stable in solid form and in medium-chain triglyceride oil solution at 25 to 40 degrees Celsius for at least three months without detectable degradation. Synthetic access to racemic CBL has been achieved through acid-catalyzed [2+2] cyclization of CBC using Montmorillonite K30 in chloroform at room temperature (60 percent yield) and through photochemical conversion under 254-nanometer ultraviolet irradiation (approximately 30 to 45 percent yield). The compound is available from analytical reference standard suppliers and from specialized cannabinoid chemical vendors at greater than 95 percent purity. This monograph reviews the chemistry, stereochemistry, and synthesis of cannabicyclol; the discovery and structural elucidation history; the 5-HT1A receptor pharmacology in molecular detail; the limited preclinical data; sourcing, handling, and quality verification considerations; and a comparative assessment of five minor cannabinoid compounds against CBL on five competency standards.